Raised 2026 HIV growth guidance to 9%-10% from 8% on Biktarvy, Yeztugo and Descovy momentum.
Expected FDA decision and U.S. launch preparations for BIC/LEN in late August 2026.
Anito-cel launch readiness ahead of Dec. 23, 2026 PDUFA; revenue expected to begin early 2027.
Potential 2027 launch of ISL/LEN, the first once-weekly oral HIV treatment regimen.
GS-8824 expected to enter registrational development in platinum-resistant ovarian cancer as early as 2027.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Gilead Sciences, Inc. and 4,900+ companies.